Cell proliferation rates in an artificial tissue-engineered environment.
Worldwide, and particularly in Europe, Japan and the USA, cardiovascular disease is a major killer. It can be treated using tissue or organ transplant surgery, but donor organs may be scarce. Tissue engineering is the integration of engineering principles and biology to produce satisfactory synthetic replacement body parts, using viable cells in a suitable matrix, for regenerative medicine. The aim of this study was to measure and compare cell proliferation kinetics after different time intervals of myofibroblasts in a synthetic matrix, thus to be able to deduce the period that a transplanted-cell population can be expected to survive in a tissue-engineered environment. Porcine aortic wall cells were grown in a porous sponge scaffold, that later could be fashioned into aortic or heart valve substitutes. Freshly acquired cells were seeded on identical sponges and were grown under normal culture conditions for a period of 4 weeks. Seeding concentration was a million cells per sponge. Cells progressively populated the sponges, both covering the surface and infiltrating the depth of the matrix, via sponge pores. Samples were taken at 1 week and at 4 weeks, and the rate of cell proliferation was determined by the metaphase arrest technique. Specimens were also taken for light and electron microscopy to determine whether these transplanted cells were capable of synthesizing their own extracellular matrix.
Sarraf
C E
CE
Department of Biomedical Sciences, University of Westminster, London, UK.
Harris
A B
AB
McCulloch
A D
AD
Eastwood
M
M
D000465:Algorithms; D000818:Animals; D001011:Aorta / Q000166:cytology; D018929:Cell Culture Techniques / Q000379:methods; D049109:Cell Proliferation; D003094:Collagen / Q000737:chemistry / Q000378:metabolism; D004549:Elastin / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism* / Q000648:ultrastructure; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology / Q000648:ultrastructure; D008677:Metaphase / Q000187:drug effects; D044968:Regenerative Medicine / Q000379:methods; D013552:Swine; D023822:Tissue Engineering / Q000379:methods*; D014750:Vincristine / Q000494:pharmacology
D016326:Extracellular Matrix Proteins; D014750:Vincristine; D003094:Collagen; D004549:Elastin